A randomized, open-label phase III trial of mapisal versus urea hand-foot cream as prophylaxis for capecitabine-induced hand-foot syndrome in patients with gastrointestinal tumors or breast cancer

n/a

Status: Studie beendet

Beteiligte

Identifier

Links

Kontakt